Napo pharmaceuticals, a jaguar health family company, submits funding application to national institute of allergy and infectious diseases for development of np-300 drug candidate for cholera-related diarrhea

Cholera is an acute diarrheal illness caused by infection of the intestine with the bacterium vibrio cholerae jaguar intends to pursue a tropical disease priority review voucher, under fda's financial incentive program, to develop np-300 for this indication san francisco, ca / accesswire / september 12, 2023 / napo pharmaceuticals (napo), a jaguar health (nasdaq:jagx) (jaguar) family company, today announced that it has submitted a grant application to the national institute of allergy and infectious diseases (niaid) for funding to support napo's phase i study of np-300, the company's novel drug product candidate for the symptomatic relief and treatment of moderate-to-severe diarrhea, with or without concomitant antimicrobial therapy, from bacterial, viral, and parasitic infections including vibrio cholerae, the bacterium that causes cholera. "i am very pleased that this grant application has been filed," said michael k.
JAGX Ratings Summary
JAGX Quant Ranking